Sensitive and Specific Detection of Low-Level Antibody Responses in Mild Middle East Respiratory Syndrome Coronavirus Infections

Middle East respiratory syndrome coronavirus (MERS-CoV) infections in humans can cause asymptomatic to fatal lower respiratory lung disease. Despite posing a probable risk for virus transmission, asymptomatic to mild infections can go unnoticed; a lack of seroconversion among some PCR-confirmed cases has been reported. We found that a MERS-CoV spike S1 protein–based ELISA, routinely used in surveillance studies, showed low sensitivity in detecting infections among PCR-confirmed patients with mild clinical symptoms and cross-reactivity of human coronavirus OC43–positive serum samples. Using in-house S1 ELISA and protein microarray, we demonstrate that most PCR-confirmed MERS-CoV case-patients with mild infections seroconverted; nonetheless, some of these samples did not have detectable levels of virus-neutralizing antibodies. The use of a sensitive and specific serologic S1-based assay can be instrumental in the accurate estimation of MERS-CoV prevalence.

Middle East respiratory syndrome coronavirus (MERS-CoV) poses a public health threat; ongoing outbreaks have been reported since its detection in 2012 (1). MERS-CoV infection may be asymptomatic or may cause illness ranging from mild to fatal; fatal infections account for 35% of reported cases (2–5). Dromedary camels are the virus reservoir (6,7), and pose a high risk of infecting humans in contact with them (4,7–9). These spillover events may seed outbreaks in the community (10), which occur mainly in healthcare settings (11,12) and, to a lesser extent, among patient household contacts (13–15). Although not sustained, human-to-human transmission accounts for most reported cases (16) and may initiate outbreaks outside endemic areas, as seen in the 2015 South Korea outbreak (17). However, the rate of human-to-human transmission and total disease burden of MERS-CoV are not fully clear because we lack accurate data on the frequency of asymptomatic and mild infections.

Diagnostic assays with validated high sensitivity and specificity are crucial to estimate the prevalence of MERS-CoV. Molecular-based assays have been developed that enable sensitive and specific diagnosis of MERS-CoV infections (18,19). Although the molecular detection of viral nucleic acid by reverse transcription PCR (RT-PCR) is the standard for MERS-CoV diagnosis, serologic detection remains necessary. Viral nucleic acid is detectable within a limited timeframe after infection, and samples from the lower respiratory tract are required for reliable results. Furthermore, whereas mutations in the viral regions where the PCR probes bind could lead to decreased sensitivity (20), genetically diverse MERS-CoV strains may retain antigenic similarity (21). Validated serologic assays are needed to ensure that the full spectrum of infections is identified; antibodies can be detected for longer periods after infection and even if viruses mutate. Several research groups and companies have developed serologic assays allowing for high-throughput surveillance for MERS-CoV infections among large populations (15,19,22–25).

Despite the number of serological assays developed, none is considered to be fully validated. There are 2 major challenges concerning specificity and sensitivity
Detection of Mild MERS-CoV Infections

aspects of MERS-CoV serologic assays. The first challenge is that 90% of the human population have antibodies against common cold-causing human coronaviruses (HCoVs) that could cross-react, resulting in false positives in serologic assays, especially in persons infected with viruses belonging to the same genus of β-coronaviruses as human seasonal coronaviruses OC43 and HKU1 (26). The spike protein, specifically its N-terminal S1 domain, is highly immunogenic and divergent among HCoVs, so it is an ideal candidate for virus-specific serologic assays (27). The second challenge is the low antibody responses among mildly infected and asymptomatic cases. Severe MERS-CoV infections result in a robust immune response allowing serologic detection in patients with positive or negative PCR outcomes (28), but PCR-diagnosed mild or asymptomatic infections may cause variable immune responses that can be undetectable by serologic assays (5,15,17). Therefore, a sensitive assay is necessary to avoid false-negative results that can cause failure in detection of subclinical infections and underestimation of prevalence in surveillance studies. We evaluated the antibody responses following severe and mild laboratory-confirmed MERS-CoV infections, validating and comparing different assay platforms for the specific and sensitive detection of MERS-CoV infections.

Materials and Methods

Serum Samples
We used a total of 292 serum samples in this study (Table 1; Appendix, https://wwwnc.cdc.gov/EID/article/2510/19-0051-App1.pdf). The samples represented patients with serologically identified (8) and PCR-confirmed MERS-CoV infections (17,29), a cohort of healthy blood donors as a control group, and patients confirmed by RT-PCR to have non–MERS-CoV respiratory virus infections to assess assay specificity. The use of serum samples from the Netherlands was approved by the Erasmus Medical Center local medical ethics committee (MEC approval 2014-414). The Institutional Ethics Review Board of Seoul National University Hospital approved the use of samples from patients in South Korea (approval no. 1506–093–681). The Ethics and Institutional Animal Care and Use Committees of the Medical Research Center, Hamad Medical Corporation, approved the use of samples from Qatar (permit 2014–01–001).

Serologic Assays
We tested all serum samples for MERS-CoV neutralizing antibodies using plaque reduction neutralization assay (PRNT). For S1 reactivity, we used a routine ELISA (iELISA; Euroimmun, https://www.euroimmun.com [15]), an in-house ELISA (iELISA), and protein microarray (8,23). For nucleocapsid reactivity, we used luciferase immunoprecipitation assay (N-LIPS) (24). For S2 reactivity, we used ELISA (Appendix).

Statistical Analyses
We evaluated the specificity and sensitivity and predictive values of the assay platforms using serum samples from patients with PCR-diagnosed MERS-CoV infections, respiratory virus–infected patients, and healthy controls. We compared performance of assay platforms to PCR performance using Fisher exact test and used receiver operating characteristic (ROC) curve to compare performance of different platforms. We performed all statistical analyses using GraphPad Prism version 7 (https://www.graphpad.com).

Results

Low Antibody Responses following Mild MERS-CoV Infection
Several studies have proposed that antibody levels and longevity following MERS-CoV infection are dependent on disease severity (5,15,17). Among PCR-confirmed MERS patients, mild infections may result in undetectable or lower, short-lived immune responses when compared with severe infections. We evaluated MERS-CoV–specific antibody responses in severe and mild MERS-CoV infections using serum samples collected 6, 9, and 12 months after disease onset from PCR-confirmed MERS-CoV patients from the 2015 South Korea outbreak, 6 with severe and 5 with mild infections (17). First, we tested serum samples for MERS-CoV S1 antibodies using different assay platforms (Figure 1; Appendix Table). Consistent with the earlier report (17), the routinely used rELISA detected only 2/6 mild infections (Figure 1, panel A). In contrast, iELISA detected 5/6 mild infections (Figure 1, panel B). Similar results were obtained using the S1 protein microarray to screen for MERS-CoV–specific antibodies (Figure 1, panel C). Although these serum samples lacked MERS-CoV neutralizing antibodies (17), the presence of nucleocapsid antibodies up to 1 year postinfection in 4/6 mildly infected patients’ samples confirmed the results of the S1 ELISA with an assay targeting another MERS-CoV protein (Figure 1, panel D). All severe cases, on the other hand, were found positive in all tested platforms up to 1 year after disease onset, indicating a robust immune response of high antibody titers in severe cases (Figure 1; Appendix Table). Compared with milder infections, both S1 and neutralizing antibody responses were higher in severely infected cases, confirming that antibody responses are lower following nonsevere infection.
RESEARCH

Specificity and Sensitivity of In-house S1 ELISA and Microarray

To confirm that the variation in the detection of mild cases is caused by the sensitivity of the different platforms used, we further validated the platforms for specificity and sensitivity using 292 serum samples (Table 1). Using MERS-CoV neutralization as the standard for MERS-CoV serology, we tested all serum samples using plaque reduction neutralization assay (PRNT) and for S1, S2, and nucleocapsid reactivities.

We assessed the specificity of the assays using serum samples from cohorts A–C: healthy blood donors (cohort A), patients with PCR-confirmed acute respiratory non-CoV infections (cohort B), and patients with acute to convalescent PCR-confirmed α- and β-HCoV infections (cohort C). None of the serum samples from specificity cohorts A–C were reactive by iELISA at the set cutoff, indicating 100% specificity (Figure 2, panel A; Appendix). We also evaluated the sensitivity for detecting MERS-CoV infections; iELISA was able to detect MERS-CoV infections among persons with camel contact (cohort D1) who had low antibody levels as determined by protein microarray (8). Using samples from acute-phase PCR-diagnosed patients (cohort E), we detected seropositivity 6–8 days postdiagnosis (dpd). All convalescent-phase serum samples (cohort F) were positive up to the last time point tested: 228 dpd for patient 1 and 44 dpd for patient 2 (Appendix Figure 1).

These results reveal the high specificity and sensitivity of this ELISA platform, supporting our earlier findings and confirming the sensitivity of our platform in detecting low immune responses among cases of milder infection (cohort G) (Figure 1). Overall, iELISA was 100% (95% CI 98.07%–100%) specific and 92.3% (11/13; 95% CI 66.7%–99.6%) sensitive for detection of PCR-confirmed cases (96.9% overall in the tested cohorts; 95% CI 84.3%–99.8%) (Table 2). Moreover, the iELISA performance was in accordance with that of the MERS-CoV S1 protein microarray (Figure 2, panel B). S1 microarray validation showed the same pattern of specificity with no false positives (100% specificity, 95% CI 98.07%–100%) in cohorts A–C and was 84.6% sensitive (95% CI 57.8%–97.3%) for PCR-confirmed cases and 93.8% overall (95% CI 79.9%–98.9%). Specificity of S1 as an antigen for MERS-CoV serology was further supported by the rates of seropositivity of all the serum samples from cohorts A–C: 87.4% for HCoV-HKU1, 91.3% for HCoV-OC43, 96.4% for HCoV-NL63, and 100% for HCoV-229E, as determined by microarray (Figure 2, panel C). All samples were seronegative for SARS-CoV, and no MERS-CoV false positives were detected in the iELISA and microarray. Overall, these results provided evidence for the use of S1 as a specific antigen for MERS-CoV serology.

We evaluated nucleocapsid and S2 antibody responses after MERS-CoV infections. At the set cutoff, none of the control serum samples tested positive for nucleocapsid antibodies (Figure 2, panel D). We detected seroconversion by nucleocapsid-luciferase immunoprecipitation assay among all severely infected, 4/6 (66.7%) mildly infected,
EMERGING INFECTIOUS DISEASES • www.cdc.gov/eid • Vol. 25, No. 10, October 2019

Detection of Mild MERS-CoV Infections

Table 1. Cohorts used in study of specificity and sensitivity of assays for MERS-CoV

| Cohort | Country       | Sample source                                      | Infection                  | No. samples | Postdiagnosis range |
|--------|---------------|----------------------------------------------------|----------------------------|-------------|---------------------|
| A      | The Netherlands | Healthy blood donors (negative cohort)             | NA                         | 50          | NA                  |
| B      | The Netherlands | Non-CoV respiratory infections†                    | Adenovirus                 | 5           | 2–4 w               |
|        |                |                                                    | Bocavirus                  | 2           | 2–4 w               |
|        |                |                                                    | Enterovirus                | 2           | 2–4 w               |
|        |                |                                                    | HMPV                       | 9           | 2–4 w               |
|        |                |                                                    | Influenza A                | 13          | 2–4 w               |
|        |                |                                                    | Influenza B                | 6           | 2–4 w               |
|        |                |                                                    | Rhinovirus                 | 9           | 2–4 w               |
|        |                |                                                    | RSV                        | 9           | 2–4 w               |
|        |                |                                                    | PIV-1                      | 4           | 2–4 w               |
|        |                |                                                    | PIV-3                      | 4           | 2–4 w               |
|        |                |                                                    | Mycoplasma pneumoniae     | 1           | 2–4 w               |
|        |                |                                                    | CMV                        | 9           | 2–4 w               |
|        |                |                                                    | EBV                        | 12          | 2–4 w               |
| C      | The Netherlands | Persons with recent CoV infections†                | e-CoV HCoV-229E            | 19          | 2 w–1 y             |
|        |                |                                                    | e-CoV HCoV-NL63            | 18          | 2 w–1 y             |
|        |                |                                                    | β-CoV HCoV-OC43            | 23          | 2 w–1 y             |
| D1     | Qatar          | S1 microarray positive persons with camel contact | NA                         | 19          | NA                  |
| D2     |                | S1 microarray negative persons with camel contact | NA                         | 18          | NA                  |
| E      | The Netherlands | RT-PCR confirmed MERS case-patients‡               | Acute‡                     | 21          | 1–14 d              |
| F      |                |                                                   | Convalescent‡              | 7           | 15–228 d            |
| G      | South Korea    | RT-PCR confirmed MERS case-patients§              | Mild infection§            | 17          | 6–12 mo             |
| H      |                |                                                   | Severe infection§          | 15          | 6–12 mo             |

*Cohorts A–C were established to test assay specificity; cohorts D–H were established to test assay sensitivity. CoV, coronavirus; CMV, cytomegalovirus; EBV, Epstein-Barr virus; HCoV, human coronavirus; HMPV, human metapneumovirus; MERS, Middle East respiratory syndrome; mo, month; NA, not applicable; PIV, parainfluenza virus; RSV, respiratory syncytial virus.

†Cross-reactivity.
‡Samples taken from 2 case-patients at different time points.
§Samples taken from 6 case-patients at different time points.
¶Samples taken from 5 case-patients at different time points.

and 5/18 (28%) asymptomatic S1-positive persons with camel contact. When testing for MERS-CoV S2–specific antibody responses, none of the control serum samples in cohorts A–C was cross-reactive (Figure 2, panel E), whereas 1/17 S1-negative samples and 1/18 S1-positive samples from persons with camel contact tested positive. These findings indicate low immune responsiveness in mild MERS cases. Thus, when comparing the use of S1, S2, and N proteins for the detection of MERS-CoV infections, S1 showed the highest specificity and sensitivity among the 3 tested proteins.

rELISA Validation

Strikingly, the routinely used ELISA showed the least sensitivity among the tested S1 platforms (Table 2; Figure 1; Figure 2, panel F). We saw this difference in the cohort of persons with camel contact from Qatar who had mild to asymptomatic infections and who were identified to be seropositive for MERS-CoV in an earlier study (8) (Figure 2, panel F, cohort D1). Although they tested seropositive by iELISA and the microarray platform, only 20% of those also tested positive using the rELISA platform. We tested different coating conditions and found that a reduction in antigen coating or a loss of some conformational epitopes could have contributed to the low sensitivity seen in the rELISA versus the iELISA, despite testing the same antigen (S1) (Figure 3). This low sensitivity confirms the likelihood of false-negative detection of some MERS-CoV cases using rELISA.

We evaluated the specificity of the rELISA platform using cohorts A–C. Among these, serum samples from 2 patients with HCoV-OC43 (a β-CoV) infection tested positive (Figure 2, panel F) but tested negative for MERS-CoV neutralization by PRNT, Western blot, immunofluorescence assay, iELISA, or S1 protein microarray (using commercial and in-house S1 proteins), indicating a false-positive reaction in the rELISA. Overall, the rELISA was 98.97% (95% CI 96.3%–99.8%) specific in the tested cohorts (Table 3). Using a lower cutoff (optical density ratio 0.4), to show 100% specificity and sensitivity, as suggested in an earlier study (30), did increase the sensitivity (from 69.2% to 84.6%), but doing so reduced specificity; numbers of false-positive results increased from 2 to 7 and specificity decreased from 98.97% to 96.4% (Appendix Figure 2).
Mild MERS-CoV infections and Neutralizing Antibodies

To investigate the difference in the neutralization responses produced following severe and mild infections and the reliability of neutralization assays as confirmatory assays for mild infections, we validated PRNT to specific and sensitive detection of MERS-CoV infections. Although none of the healthy blood donors (cohort A) were reactive, the respiratory patients (cohorts B and C) showed low levels of cross-neutralization (titer 20) in 12 serum samples. One sample with a titer of 80 (Figure 2, panel G) was from an HCoV-OC43 patient; none of the serum samples tested negative for S1 antibodies in all tested platforms (Table 3); none of the serum samples was positive in 2 assays. For PCR-diagnosed MERS cases (cohorts E–H), PRNT showed 100% sensitivity for detecting severe cases after the seroconversion period (>14 dpd; cohort F) and for up to 1 year (cohort H), indicating strong neutralizing antibody responses.

In contrast, results varied for mild cases (cohort G). Neutralizing antibodies were detected in 3/6 (50%) of mild
Detection of Mild MERS-CoV Infections

infections (Appendix Table 1), highlighting lower, shorter-lived neutralizing responses among mild cases. This finding is consistent with the results of a cohort of mild to asymptomatic MERS-CoV–infected persons with camel contact from Qatar (8) (Figure 2, panel G, cohort D1). These persons had low to undetectable neutralizing antibodies while being reactive to S1 on the protein microarray platform and in our iELISA.

Nonneutralizing Antibodies after Mild MERS-CoV Infections

For the PCR-confirmed MERS-CoV patients (cohorts E–H) and serologically positive persons with camel contact (cohort D1), S1 antibody titers as determined by iELISA strongly correlated with neutralization titers (Figure 5, panel A), showing that S1 antibody response is a reliable predictor of neutralization activity. This finding indicates that a population of mildly infected patients with S1-reactive antibodies but no detectable neutralizing antibodies could easily be missed in attempts to confirm cases by neutralization assay.

Discussion

Serologic detection of MERS-CoV exposure is valuable for identifying asymptomatic cases and virus reservoirs in population screening and epidemiologic studies, as well as for contact investigations. Detection aids in understanding the host immune response to the virus, identifying key viral immunogens, and mapping key neutralizing antibodies, which all lead to implementing appropriate preventive and therapeutic measures. Antibody responses varied among PCR-confirmed MERS-CoV cases; case-patients with mild and asymptomatic infections showed low or undetectable seroconversion, in contrast to severe infections that resulted in robust responses (5,17,31). The low-level antibody responses produced following nonsevere infections led to failure in detecting such responses in some patients by a routinely used ELISA and neutralization assays (5,17,32). This result may have impeded estimation of prevalence of virus infections in surveillance studies. We were able to detect nonneutralizing antibody responses among previously infected mild and asymptomatic cases that were previously unidentified; this finding indicates that MERS-CoV

| Table 2. Specificity and sensitivity of assay platforms for the detection of MERS-CoV antibodies among PCR-confirmed cases* |
|---------------------------------------------------------------|
| Test characteristic | In-house S1 ELISA | S1 microarray | PRNT<sub>90</sub> | Routinely used S1 ELISA |
|---------------------|------------------|---------------|----------------|------------------------|
| p value             | <0.0001          | <0.0001       | <0.0001        | <0.0001                |
| Sensitivity, N = 13 |                  |               |                |                        |
| No. tested positive |                  |               |                |                        |
| n/N value (95% CI)  | 0.9231 (0.6669–0.9961) | 0.8462 (0.5777–0.9727) | 0.692 (0.4237–0.8732) | 0.6923 (0.4237–0.8732) |
| Specificity, N = 195|                  |               |                |                        |
| No. tested positive |                  |               |                |                        |
| n/N value (95% CI)  | 0               | 1             | 1              | 2                      |
| Positive predictive value (95% CI) | 1 (0.9807–1) | 1 (0.9807–1) | 0.9949 (0.9715–0.9997) | 0.9897 (0.9634–0.9982) |
| Negative predictive value (95% CI) | 0.9949 (0.9717–0.9997) | 0.9898 (0.9637–0.9982) | 0.9798 (0.9492–0.9921) | 0.9797 (0.949–0.9921) |
| Positive likelihood ratio | NA | NA | NA | 135 | 67.5 |
| Area under the ROC curve | 0.9949 | 0.9898 | 0.9798 | 0.9797 |
| Area | 1 | 0.9893 | 0.7348 | 0.9481 |
| SE | 0 | 0.005409 | 0.07513 | 0.01767 |
| 95% CI | 1–1 | 0.9787–0.9999 | 0.5876–0.8821 | 0.9134–0.9827 |
| p value | <0.0001 | <0.0001 | <0.0001 | <0.0001 |

*p value calculated by Fisher exact test. CoV, coronavirus; MERS, Middle East respiratory syndrome; NA, not applicable; PRNT, plaque reduction neutralization test; PRNT<sub>90</sub>, 90% endpoint PRNT; ROC, receiver operating characteristic.

A

![Camel contacts and S1 ELISA OD](image)

B

![Neutralization assay](image)

Figure 3. Low sensitivity of commercial S1 ELISA shown as the effect of lowering coating antigen concentration (A) or antigen denaturation (B) on the sensitivity of antibody detection among Middle East respiratory syndrome coronavirus–infected persons with camel contact. All samples were seropositive by in-house S1 ELISA and microarray. Dark blue indicates those that tested seropositive by commercial S1 ELISA.
prevalence could be higher than current estimates and that using sensitive platforms could lead to more precise calculation of incidence rates.

Although an earlier study evaluating serologic responses among PCR-confirmed MERS patients reported seroconversion in only 2/6 (33%) mildly infected cases (17), we were able to detect 5/6 (83.5%) by our in-house S1 ELISA and 4/6 (67%) by microarray. S1 iELISA and microarray were highly sensitive for detecting MERS-CoV infections, showing 100% specificity in the tested cohorts. Although the rELISA platform detected severe infections with no false negatives, it did not detect seroconversion among some mildly infected PCR-confirmed and asymptomatic persons with camel contact who had low antibody responses. In addition, rELISA results showed cross-reactivity with some serum samples from HCoV-OC43–infected persons. The variation in the reactivity between the 2 ELISA platforms could be attributed to the difference in the coating protein preparations used in each or to the reduced stability of the protein during storage of the rELISA platform.

Overall, our results validate the use of S1 as a specific antigen for MERS-CoV serology if folding is correct, providing a highly specific 1-step diagnostic approach without false positives omitting the need for a confirmatory assay. In particular, neutralizing antibodies were undetectable after most asymptomatic and some mild infections. Using 50% instead of 90% reduction as a cutoff for PRNT can increase the sensitivity of the assay for confirming mild or asymptomatic infections.

Table 3. Sensitivity and specificity results of routinely used commercial S1 ELISA and PRNT90 assays for MERS-CoV*

| Assay parameter and sample source | Infection | No. positive/no. tested | Specificity or sensitivity, % |
|----------------------------------|-----------|-------------------------|-------------------------------|
|                                  |           | S1 rELISA† | S1-positive | S1-negative | PRNT90 (titer) | |
| **Specificity**                  |           | S1 rELISA† | S1-positive | S1-negative | PRNT90 (titer) | |
| Healthy blood donors             | None      | 0/50        | NA          | 0/50        | 98.97          | 93.33 (1:20); 99.5 (1:40) |
| Non-CoV respiratory infections   | Adenovirus| 0/5         | NA          | 0/5         | 93.33 (1:20); 99.5 (1:40) |
|                                  | Bocavirus | 0/2         | NA          | 0/2         | 93.33 (1:20); 99.5 (1:40) |
|                                  | Enterovirus| 0/2        | NA          | 0/2         | 93.33 (1:20); 99.5 (1:40) |
|                                  | HMPV      | 0/9         | NA          | 0/9         | 93.33 (1:20); 99.5 (1:40) |
|                                  | Influenza A| 0/13      | NA          | 4/13 (20, | 93.33 (1:20); 99.5 (1:40) |
|                                  |           |            |             | 20, 20, 20) |             | |
|                                 | Influenza B| 0/6        | NA          | 0/6         | 93.33 (1:20); 99.5 (1:40) |
|                                 | Rhinovirus| 0/9         | NA          | 2/9 (20, 20) | 93.33 (1:20); 99.5 (1:40) |
|                                 | RSV       | 0/9         | NA          | 1/9 (20)    | 93.33 (1:20); 99.5 (1:40) |
|                                 | PIV-1     | 0/4         | NA          | 0/4         | 93.33 (1:20); 99.5 (1:40) |
|                                 | PIV-3     | 0/4         | NA          | 0/4         | 93.33 (1:20); 99.5 (1:40) |
|                                 | Mycoplasma| 0/1         | NA          | 0/1         | 93.33 (1:20); 99.5 (1:40) |
|                                 | CMV       | 0/9         | NA          | 0/9         | 93.33 (1:20); 99.5 (1:40) |
|                                 | EBV       | 0/12        | NA          | 0/12        | 93.33 (1:20); 99.5 (1:40) |
| Recent CoV infections‡          | α-CoV HCoV-229E | 0/19     | NA          | 3/19 (20, | 93.33 (1:20); 99.5 (1:40) |
|                                 |           |            |             | 20, 20)    |             | |
|                                 | α-CoV HCoV-NL63 | 0/18    | NA          | 0/18        | 93.33 (1:20); 99.5 (1:40) |
|                                 | β-CoV HCoV-OC43 | 2/23    | 0/2         | 1/21 (80)  | 93.33 (1:20); 99.5 (1:40) |
| **Sensitivity**                 |           | S1 iELISA† | S1-positive | S1-negative | PRNT90 (titer) | |
| Persons with camel contact       | S1-microarray positive§ | 4/19 | 4/4 (40, 40, 40, 20) | 6/15 (40, 40, 20, 20, 20) | 21 | 52.6 |
|                                  | S1-microarray negative| 0/18 | NA          | 1/18 (20)  | NA            | NA |
| RT-PCR–confirmed MERS cases      | <14 d postdiagnosis | 11/21 | 11/11 | 1/10 (80) | NA            | NA |
|                                  | >14 d postdiagnosis | 7/7   | 7/7        | NA          | 100           | 100 |
|                                  | 6–12 mo postdiagnosis; mild infection | 5/17 | 5/5        | NA          | 35.3          | 35.3 |
|                                  | 6–12 mo postdiagnosis; severe infection | 15/15 | 15/15 | NA          | 100           | 100 |

*CMV, cytomegalovirus; CoV, coronavirus; EBV, Epstein-Barr virus; ELISA, enzyme-linked immunosorbent assay; HCoV, human coronavirus; HMPV, human metapneumovirus; MERS, Middle East respiratory syndrome; NA, not applicable; PIV, parainfluenza virus; PRNT, plaque reduction neutralization test; PRNT90, 90% endpoint PRNT; rELISA, routine ELISA; RSV, respiratory syncytial virus; RT-PCR, reverse transcription PCR.
†None of the serum samples from specificity cohorts tested positive by in-house S1 ELISA or microarray.
‡Cross-reactivity.
§All 19 serum samples (protein microarray positive) tested positive by in-house S1 ELISA.
infections (15,21,33), but it is crucial to precede PRNT with a sensitive screening assay to avoid false-negative results.

Prolonged viral shedding observed in severely infected patients but not in patients with mild infections (5,17,34) indicated that a short-lived infection in nonsevere cases may account for lower antibody responses, including functional neutralizing antibodies. A possible reason is that nonneutralizing antibodies comprise a substantial proportion of antibodies elicited against viral proteins, including immature forms of surface proteins, released through lysis of infected cells following a short-lived abortive infection (35,36). We found that spike antibody titers were produced at higher titers than nucleocapsid antibodies and neutralizing antibodies were undetectable following nonsevere infections. These findings indicate that anti-spike antibodies are more sensitive predictors for previous MERS-CoV infections, especially mild and asymptomatic infections, and that conducting neutralization assays to confirm serologic findings, as recommended by the World Health Organization (37), could result in potential underestimation of the true prevalence in epidemiologic studies.

Further studies testing patients with previously indeterminate infection could provide further clues on the epidemiology of MERS-CoV. A recent study reported the presence of MERS-CoV–specific CD8+ T-cell responses after MERS-CoV infection, irrespective of disease severity (38). Therefore, T-cell assays can be used to confirm serologic findings in epidemiologic studies (mainly asymptomatic cases) instead of neutralization assays that could yield underestimated results. However, further studies are needed to rule out possible T-cell cross-reactivity with other HCoV.

Despite the use of 90% reduction as endpoint for PRNT, we observed cross-neutralization in the respiratory panel samples (13/195). All but 1 sample had a titer of 20, and all 13 were S1 negative. We reported a similar finding in an earlier study, where 1 of 35 S1-negative serum samples had a neutralization titer of 20 (8). This finding was unexpected because neutralization assays, with their high specificity, are considered the standard for...
MERS-CoV serodiagnosis. Such seemingly false positives could be attributed to the presence of natural antibodies or cross-reactive HCoV antibodies (15,32,35,39).

Cross-neutralization among human coronaviruses has rarely been reported. Chan et al. described cross-neutralization between SARS-CoV and MERS-CoV at low titers (<20) (32). However, these serum samples also tested positive for HCoV-OC43 neutralization. This finding, along with ours, raises the probability that HCoV-OC43 antibodies caused cross-reactivity; antibodies in the serum sample could be recognizing an epitope outside S1 and thus not detected in ELISA. Of interest, we detected an HCoV-OC43 patient serum sample that could neutralize MERS-CoV at PRNT₉₀ titer ≤80, but we found that the patient received an oncolytic medication shown to have antiviral activity (40). This finding could also be a probable reason for the observed cross-neutralization. Overall, while serum samples from healthy blood donors showed no cross-neutralization or cross-reactivity to S2 or N proteins, we observed some cross-neutralization and comparably higher reactivity to S2 and N proteins in serum samples of patients with respiratory infections, which we did not detect by our in-house S1 platforms. Thus, we could not avoid cross-reactivity to S2 and N proteins, leading to false positives, without loss of sensitivity. The high specificity of the S1 protein enabled us to set a cutoff high enough to ensure specificity without losing sensitivity.

Using S1 in optimized platforms enabled us to detect seroconversion among otherwise unrecognized nonsevere MERS-CoV cases with very high sensitivity and 100% specificity. Our findings indicate that our iELISA and microarray for MERS-CoV diagnostics (Table 2; Figure 5, panel B) could be reliable diagnostic tools for identifying MERS-CoV infections. For further standardization of the assay, a calibrator (e.g., monoclonal antibody) can be included in each run to avoid intraassay variations.

Although further testing on a larger cohort may be required to rule out cross-reactivity, ensure sensitivity, and thereby validate general use as a 1-step diagnostic assay, the data obtained in this study indicate that cross-reactivity between HCoVs (at least when testing for MERS-CoV and SARS-CoV reactivity) is unlikely to occur when using optimized platforms with the divergent S1 protein. A more recent follow-up study revealed that, among 454 serum samples tested using our in-house S1 ELISA, including those from persons with camel contact, only 2 samples, both MERS-CoV–neutralization positive, tested positive whereas all other serum samples were found to be negative in the iELISA (R. Bassal et al., unpub. data). Thus, in principle, low-level antibody responses among nonsevere MERS-CoV cases may be revealed by a single ELISA test.

Because patients with mild or asymptomatic infections do not develop severe illness and thus go unrecognized, they might play a role in spreading the virus into the community, initiating outbreaks in which index case-patients report no history of camel or patient exposure. Therefore, defining the subclinical burden of infection will enable better understanding of the extent, severity, and public health threat posed by MERS-CoV, which, in turn, will guide the development and implementation of proper strategies to contain and prevent ongoing outbreaks of infection with this virus.

This work was supported by the Zoonoses Anticipation and Preparedness Initiative (ZAPI project; IMI grant agreement no. 115760), with the assistance and financial support of IMI and the European Commission, in-kind contributions from EFPIA partners.

About the Author
Ms. Okba is a PhD candidate in the viroscience department of Erasmus Medical Center, Rotterdam, the Netherlands. Her research interests include the development of diagnostic and intervention strategies for emerging viruses.

References
1. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367:1814–20. https://doi.org/10.1056/NEJMoa1211721
2. World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV) [cited 2017 Jul 16]. http://www.who.int/emergencies/mers-cov
3. Puzelli S, Azzi A, Santini MG, Di Martino A, Facchini M, Castrucci MR, et al. Investigation of an imported case of Middle East respiratory syndrome coronavirus (MERS-CoV) infection in Florence, Italy, May to June 2013. Euro Surveill. 2013;18:20564. https://doi.org/10.2807/1560-7917.ES2013.18.34.20564
4. Al Hammadi ZM, Chu DK, Eltahir YM, Al Hosani F, Al Mulla M, Tamrini W, et al. Asymptomatic MERS-CoV infection in humans possibly linked to infected dromedaries imported from Oman to United Arab Emirates, May 2015. Emerg Infect Dis. 2015;21:2197–200. https://doi.org/10.3201/eid2112.151132
5. Alshukairi AN, Khalid I, Ahmed WA, Dada AM, Bayumi DT, Malic LS, et al. Antibody response and disease severity in healthcare worker MERS survivors. Emerg Infect Dis. 2016;22. https://doi.org/10.3201/eid2206.160010
6. Reusken CB, Haagmans BL, Müller MA, Gutierrez C, Godeke GJ, Meyer B, et al. Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. Lancet Infect Dis. 2013;13:859–66. https://doi.org/10.1016/S1473-3099(13)70164-6
7. Haagmans BL, Al Dahairy SH, Reusken CB, Raj VS, Galiano M, Myers R, et al. Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation. Lancet Infect Dis. 2014;14:140–5. https://doi.org/10.1016/S1473-3099(13)70690-X
8. Reusken CB, Farag EA, Haagmans BL, Mohran KA, Godeke GV, Raj S, et al. Occupational exposure to dromedaries and risk for MERS-CoV infection, Qatar, 2013–2014. Emerg Infect Dis. 2015;21:1422–5. https://doi.org/10.3201/eid2108.150481
9. Müller MA, Meyer B, Corman VM, Al-Masri M, Turkestani A, Ritze D, et al. Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study. Lancet Infect Dis. 2015;15:559–64. https://doi.org/10.1016/S1473-3099(15)70090-3
10. Kayali G, Peiris M. A more detailed picture of the epidemiology of Middle East respiratory syndrome coronavirus. Lancet Infect Dis. 2015;15:495–7. https://doi.org/10.1016/S1473-3099(15)70128-3
11. Assiri AM, Biggs HM, Abedi GR, Lu X, Bin Saeed A, Abdalla O, et al. Increase in Middle East respiratory syndrome-coronavirus cases in Saudi Arabia linked to hospital outbreak with continued circulation of recombinant virus, July 1–August 31, 2015. Open Forum Infect Dis. 2016;3:ofw165. https://doi.org/10.1093/ofid/ofw165

12. Park JW, Lee KJ, Lee KH, Lee SH, Cho JR, Mo JW, et al. Hospital outbreaks of Middle East respiratory syndrome, Daejeon, South Korea, 2015. Emerg Infect Dis. 2017;23:898–905. https://doi.org/10.3201/eid2306.161020

13. Memish ZA, Zumla AI, Al-Hakeem RF, Al-Rabeah AA, Stephens GM. Family cluster of Middle East respiratory syndrome coronavirus infections. N Engl J Med. 2013;368:2487–94. https://doi.org/10.1056/NEJMoa1303729

14. Assiri A, McGeer A, Perl TM, Price CS, Al Rabeelah AA, Cummings DA, et al.; KSA MERS-CoV Investigation Team. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med. 2013;369:407–16. https://doi.org/10.1056/NEJMoa1306742

15. Drosten C, Meyer B, Müller MA, Corman VM, Al-Masri M, Hossain R, et al. Transmission of MERS-coronavirus in household contacts. N Engl J Med. 2014;371:828–35. https://doi.org/10.1056/NEJMoa1405858

16. Alenaziy FS, Mohamed N, Alqabtani FY, El Hadi Mohamed RA. Outbreak of Middle East respiratory syndrome coronavirus in Saudi Arabia: a retrospective study. BMC Infect Dis. 2017;17:23. https://doi.org/10.1186/s12879-016-2137-3

17. Choe PG, Perera RAPM, Park WB, Song KH, Bang JH, Kim ES, et al. MERS-CoV antibody responses 1 year after symptom onset, South Korea, 2015. Emerg Infect Dis. 2017;23:1079–84. https://doi.org/10.3201/eid2307.170310

18. Corman VM, Eckerle I, Bleicker T, Zaki A, Landt O, Eschbach-Bludau M, et al. Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction. Euro Surveill. 2012;17:20285. https://doi.org/10.2807/ese.17.39.20285-en

19. Corman VM, Müller MA, Costabel U, Timm J, Binger T, Meyer B, et al. Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections. Euro Surveill. 2012;17:20334. https://doi.org/10.2807/ese.17.49.20334-en

20. Furuse Y, Okamoto M, Oshitani H. Conservation of nucleotide sequences for molecular diagnosis of Middle East respiratory syndrome coronavirus. 2015. Int J Infect Dis. 2015;40:25–7. https://doi.org/10.1016/j.ijid.2015.09.018

21. Park SW, Perera RA, Choe PG, Lau EH, Choi SJ, Chun JY, et al. Comparison of serological assays in human Middle East respiratory syndrome (MERS)–coronavirus infection. Euro Surveill. 2015;20:30042. https://doi.org/10.2807/1560-7917.ES.2015.20.41.30042

22. Al-Abdallat MM, Payne DC, Alqasrawi S, Rha B, Tohme RA, Abedi GR, et al.; Jordan MERS-CoV Investigation Team. Hospital-associated outbreak of Middle East respiratory syndrome coronavirus: a serologic, epidemiologic, and clinical description. Clin Infect Dis. 2014;59:1225–33. https://doi.org/10.1093/cid/ciu359

23. Reusken C, Mou H, Godeke GJ, van der Hoek L, Meyer B, et al. Specific serology for emerging human coronavirus: significance for subunit vaccines. J Virol. 1999;73:2956–62.

24. Alagaili AN, Briese T, Mishra N, Kapoor V, Sameroff SC, Burbelo PD, et al. Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia. MBio. 2014;5:e01002–14. https://doi.org/10.1128/mBio.01002-14

25. Perera RA, Wang P, Gomaa MR, El-Shesheny R, Kandeil A, Bagato O, et al. Seroepidemiology for MERS coronavirus using microneutralisation and pseudoparticle virus neutralisation assays reveal a high prevalence of antibody in dromedary camels in Egypt, June 2013. Euro Surveill. 2013;18:20574. https://doi.org/10.2807/1560-7917.ESS2013.18.36.20574

26. Meyer B, Müller MA, Corman VM, Reusken CB, Ritz D, Godeke GJ, et al. Antibodies against MERS coronavirus in dromedary camels, United Arab Emirates, 2003 and 2013. Emerg Infect Dis. 2014;20:552–9. https://doi.org/10.3201/eid2004.131746

27. Meyer B, Drosten C, Müller MA. Serological assays for emerging coronaviruses: challenges and pitfalls. Virus Res. 2014;194:175–83. https://doi.org/10.1016/j.virusres.2014.03.018

28. Payne DC, Iblan I, Rha B, Alqasrawi S, Haddadin A, Al Nsour M, et al. Persistence of antibodies against Middle East respiratory syndrome coronavirus. Emerg Infect Dis. 2016;22:1824–6. https://doi.org/10.3201/eid2210.160706

29. Fanoy EB, van der Sande MA, Kraaij-Dirkzwager M, Dirksen K, Jonges M, van der Hoek W, et al. Travel-related MERS-CoV cases: an assessment of exposures and risk factors in a group of Dutch travelers returning from the Kingdom of Saudi Arabia, May 2014. Emerg Themes Epidemiol. 2014;11:16. https://doi.org/10.1186/1742-7622-11-16

30. Ko JH, Muller MA, Seok H, Park GE, Lee JY, Cho SY, et al. Suggested new breakthroughs of anti-MERS-CoV antibody ELISA titers: performance analysis of serologic tests. Eur J Clin Microbiol Infect Dis. 2017;36:2179–86.

31. Ko JH, Muller MA, Seok H, Park GE, Lee JY, Cho SY, et al. Serologic responses of 42 MERS-coronavirus-infected patients according to the disease severity. Diagn Microbiol Infect Dis. 2017;89:106–11. https://doi.org/10.1016/j.diagmicrobio.2017.07.006

32. Chan KH, Chan JF, Tse H, Chen H, Lau CC, Cai JP, et al. Cross-reactive antibodies in convalescent SARS patients’ sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests. J Infect. 2013;67:130–40. https://doi.org/10.1016/j.jinf.2013.03.015

33. Liljander A, Meyer B, Jones J, Müller MA, Lattowe E, Njeru I, et al. MERS-CoV antibodies in humans, Africa, 2013–2014. Emerg Infect Dis. 2016;22:1086–9. https://doi.org/10.3201/eid2206.160064

34. Oh MD, Park WB, Choe PG, Choi SJ, Kim JI, Chae J, et al. Viral load kinetics of MERS coronavirus infection. N Engl J Med. 2016;375:1303–5. https://doi.org/10.1056/NEJMoa1511695

35. Hangartner L, Zinkernagel RM, Hengartner H. Antiviral antibody responses: the two extremes of a wide spectrum. Nat Rev Immunol. 2006;6:231–43. https://doi.org/10.1038/nri1783

36. Sakurai H, Williamson RA, Crowe JE, Beeler JA, Poignard P, Cummings DA, et al.; KSA MERS-CoV Investigation Team. Assessment of serological responses: the two extremes of a wide spectrum. Immunity. 2015;42:1315–26. https://doi.org/10.1016/j.immuni.2015.09.018

37. World Health Organization. Laboratory testing for Middle East respiratory syndrome coronavirus, interim guidance (WHO/MERS/LAB/15.1/Rev1/2018). Geneva: The Organization; 2018.

38. Zhao J, Alshukairi AN, Babaroon SA, Ahmed WA, Bokhari AA, Nehdi AM, et al. Recovery from the Middle East respiratory syndrome is associated with antibody and T-cell responses. Sci Immunol. 2017;2:eaam5393. https://doi.org/10.1126/sciimmunol.aam5393

39. Buchholz U, Müller MA, Nitsche A, Sanewski A, Wevering N, Gangemi D, et al. Transmission of MERS-CoV in household contacts of a patient in Germany, 2015. Emerg Infect Dis. 2016;22:1086–9. https://doi.org/10.3201/eid2210.150706

40. Patel DA, Patel AC, Nolan WC, Zhang Y, Holtzman MJ. High throughput screening for small molecule enhancers of the interferon signaling pathway to drive next-generation antiviral drug discovery. PLoS One. 2012;7:e36594. https://doi.org/10.1371/journal.pone.0036594

Address for correspondence: Bart L. Haagmans, Erasmus Medical Center, Department of Viroscience, PO Box 2040, 3000 CA Rotterdam, the Netherlands; email: b.haagmans@erasmusmc.nl
Sensitive and Specific Detection of Low-Level Antibody Responses in Mild Middle East Respiratory Syndrome Coronavirus Infections

Appendix

Serum Samples

We collected serum samples from 50 healthy blood donors (Cohort A) as negative controls Sanquin Blood Bank (Rotterdam, the Netherlands) obtained written informed consent for research use. We assessed specificity using cohorts B and C, which consisted of 145 serum specimens from patients confirmed by RT-PCR to be positive for human respiratory infections. Those included samples from persons recently infected with 13 different respiratory viruses, or with acute IgM-positive CMV and EBV infection, which are known to be cross-reactive in serologic assays; as well as *Mycoplasma pneumoniae*. Because MERS has no pathognomonic signs distinguishing it from other respiratory infections, cohort B, including 85 samples from acute non-HCoV respiratory infections, was used to assess specificity in acute cases. To further evaluate specificity, cohort C included serum samples from acute to convalescent HCoV-NL63, −229E, and -OC43 patients. Furthermore, we assessed Cohorts D-G were used to evaluate sensitivity of the different platforms. Serologically identified MERS-CoV–infected mild and asymptomatic persons with camel contact (D1) and healthy donors (D2) from Qatar characterized in an earlier study (1) constituted cohort D. Serial serum samples from 2 RT-PCR–diagnosed MERS-CoV case-patients imported to the Netherlands (2) were used as positive controls and to evaluate antibody kinetics; these were 15 serum samples from patient 1, ranging 4–228 days postdiagnosis (dpd), and 13 from patient 2, ranging 1–44 dpd. These 28 samples were categorized into cohorts E (<14 dpd, acute phase) and F (>14 dpd, convalescent phase). Finally, samples from the PCR-diagnosed mild (cohort G) and severely (cohort H) infected MERS-CoV case-patients from South Korea, described earlier (34), formed the last 2 cohorts.
All samples were stored at −20°C until use. The use of serum samples from the Netherlands was approved by the local medical ethical committee (MEC approval: 2014–414). The Institutional Ethics Review Board of Seoul National University Hospital approved use of samples from South Korea (approval no. 1506–093–681). The Ethics and Institutional Animal Care and Use Committees of the Medical Research Center, Hamad Medical Corporation, approved the use of samples from Qatar (permit 2014–01–001).

**Protein Expression**

We expressed MERS S1 (amino acids 1–751) in HEK-293T cells as a C-terminal human IgG Fc (hFc) tagged protein. We purified S1-hFc protein using protein A sepharose beads (ThermoFisher Scientific, https://www.thermofisher.com) and cleaved off the hFc domain using Factor Xa (EMD Millipore, http://www.emdmillipore.com). We used X-arrest Agarose (EMD Millipore, http://www.emdmillipore.com) to obtain soluble S1 after removal of Factor Xa; S1 protein was used for coating our in-house S1 ELISA plates and microarray.

Spike S1 proteins of other HCoVs, –HKU1 (residues 1–750), –OC43 (residues 1–760), NL63 (residues 1–717), 229E (residues 1–537), and SARS-CoV (residues 1–676), were expressed as C-terminal murine IgG2a Fc tagged proteins as described earlier (5) and used for coating S1 protein microarray.

Recombinant MERS-CoV spike S2 subunit (amino acids 752–1262) was produced in the baculovirus expression system. Briefly, we cloned the codon-optimized MERS-CoV S2 encoding sequence into the pFastbac transfer vector (Invitrogen, https://www.thermofisher.com) in-frame between honeybee melittin (HBM) secretion signal peptide and a triple StrepTag purification tag. We produced acmid DNA and recombinant baculovirus according to protocols from the Bac-to-Bac system (Invitrogen). We expressed MERS-CoV S2 protein in Sf-9 cells after infection with the recombinant baculovirus. We harvested recombinant S2 from cell culture supernatants 3 days postinfection and purified it using StrepTactin sepharose affinity chromatography (IBA, https://www.iba-lifesciences.com). The protein was used to coat ELISA plates.
PRNT

PRNT was used as a reference for this study, because it is the standard for MERS-CoV serology. We tested serum samples for their neutralization capacity against MERS-CoV (Erasmus MC isolate) by plaque-reduction neutralization test (PRNT) using Huh-7 cells in a 96-well plate format. Heat-inactivated samples were 2-fold serially diluted (1:20 up to 1:2560) in RPMI1640 medium supplemented with penicillin, streptomycin, and 1% fetal bovine serum, starting at a dilution of 1:10 in 50 μL. We added 50 μL of the virus suspension to each well (500 TCID₅₀) and incubated at 37°C for 1 h. Following incubation, we transferred the mixtures (virus and serum) on Huh-7 cells cultured in 96-well plates and incubated them at 37°C for 8 h. We then fixed the cells and stained them with immunofluorescent staining. The serum neutralization titer is the reciprocal of the highest dilution resulting in an infection reduction of ≥90% (PRNT₉₀). A titer of ≥20 was considered to be positive.

S1 ELISA

We performed MERS-CoV IgG S1 ELISA using a commercial kit (Euroimmun, https://www.euroimmun.com) and performed the assay according to manufacturer’s protocol. The optical density (OD) was measured at 450 nm, and a ratio of the reading of each sample to the reading of the calibrator, included in the kit, was calculated for each sample (OD ratio). According to the manufacturer’s guidelines, samples with an OD ratio <0.8 were considered negative, those with an OD ratio >1.1 were considered positive, whereas those in between were considered borderline.

We performed inhouse S1 ELISA by coating 96-well microtiter ELISA plates with MERS-CoV S1 protein (1 μg/mL) in PBS overnight at 4°C. Following blocking, diluted serum (1:100 or 2-fold serially diluted [1:100–1:12800] for titers) were added and incubated at 37°C for 1h. Bound antibodies were detected using peroxidase-labeled rabbit anti–human IgG (Dako, https://www.agilent.com) and TMB as a substrate. The absorbance of each sample was measured at 450 nm. We set a cutoff at 0.5, which is >6 standard deviations above the mean value of the negative respiratory cohort (0.46). Serum titers correspond to the reciprocal of the highest dilution giving a signal above the cutoff. We tested all samples twice in 2 independent assays.
S1 Protein Microarray

We diluted serum 4-fold (1:20 to 1:1280) and tested using an HCoV S1 protein microarray as previously described (6); including S1 domains of the 6 known HCoVs. We set a cutoff was set at 30,000 relative fluorescent units and determined serum titers as the reciprocal of the serum dilution corresponding to the EC50 of each serum sample interpolated from a concentration-response curve (7).

N-LIPS Assay

Anti-nucleocapsid antibody responses were tested using a luciferase immunoprecipitation assay (LIPS). The N protein was expressed in HEK-293T cells as an N terminal Renilla luciferase (Ruc)-tagged protein (Ruc-N) using pREN2 expression vector kindly provided by Dr. Peter D. Burbelo (8). The cells were harvested in lysis buffer (50 mM Tris [pH 7.5], 100 mM NaCl, 5 mM MgCl2, 1% Triton X-100, 50% glycerol, protease inhibitors), and the luminescence units (LU) per μL was used as a measure of antigen concentration in cell lysates. We conducted LIPS assay according to Burbelo et al. (9) with minor modifications. Briefly, we diluted serum 1:10 in buffer A (50 mM Tris [pH 7.5], 100 mM NaCl, 5 mM MgCl2, 1% Triton X-100). Then we incubated a mixture containing 10 μL of diluted serum and 1× 10^7 RLU of Ruc-Ag in a total volume of 100 μL of buffer A per well at room temperature on a rotary shaker for 1 h. We transferred the mixture containing antigen-antibody complex (100 μL) into MultiScreenHTS BV Filter Plate (Merck Millipore, https://www.merckmillipore.com) containing 5 μL of a 30% suspension of UltraLink protein A/G beads and reincubated under the same conditions for 1 more hour. After that, the wells were washed 8 times with buffer A and twice with PBS and luminescence was measured for each well after adding 100μL of 0.1 μM coelenterazine (Nanolight Technology, www.nanolight.com) in assay buffer (50 mM potassium phosphate, pH 7.4, 500 mM NaCl, 1 mM EDTA). We tested serum samples in duplicates in ≥2 independent assays and averaged the data to determine the LU value for each sample. A cutoff was set at 30,000 LU.
S2 ELISA

We conducted MERS-CoV IgG S2 ELISA following the same protocol used for the inhouse S1 ELISA. A cutoff was set at 0.72, which is equal to 6 standard deviations above the mean value of the negative cohorts.

References

1. Reusken CB, Farag EA, Haagmans BL, Mohran KA, Godeke GJ V, Raj S, et al. Occupational exposure to dromedaries and risk for MERS-CoV infection, Qatar, 2013–2014. Emerg Infect Dis. 2015;21:1422–5. PubMed https://doi.org/10.3201/eid2108.150481

2. Fanoy EB, van der Sande MA, Kraaij-Dirkzwager M, Dirksen K, Jonges M, van der Hoek W, et al. Travel-related MERS-CoV cases: an assessment of exposures and risk factors in a group of Dutch travellers returning from the Kingdom of Saudi Arabia, May 2014. Emerg Themes Epidemiol. 2014;11:16. PubMed https://doi.org/10.1186/1742-7622-11-16

3. Choe PG, Perera RAPM, Park WB, Song KH, Bang JH, Kim ES, et al. MERS-CoV antibody responses 1 year after symptom onset, South Korea, 2015. Emerg Infect Dis. 2017;23:1079–84. PubMed https://doi.org/10.3201/eid2307.170310

4. Oh MD, Park WB, Choe PG, Choi SJ, Kim Ji, Chae J, et al. Viral load kinetics of MERS coronavirus infection. N Engl J Med. 2016;375:1303–5. PubMed https://doi.org/10.1056/NEJMc1511695

5. Li W, Hulswit RJG, Widjaja I, Raj VS, McBride R, Peng W, et al. Identification of sialic acid-binding function for the Middle East respiratory syndrome coronavirus spike glycoprotein. Proc Natl Acad Sci U S A. 2017;114:E8508–17. PubMed https://doi.org/10.1073/pnas.1712592114

6. Reusken C, Mou H, Godeke GJ, van der Hoek L, Meyer B, Müller MA, et al. Specific serology for emerging human coronaviruses by protein microarray. Euro Surveill. 2013;18:20441. PubMed https://doi.org/10.2807/1560-7917.ES2013.18.14.20441

7. Koopmans M, de Bruin E, Godeke GJ, Friesema I, van Gageldonk R, Schipper M, et al. Profiling of humoral immune responses to influenza viruses by using protein microarray. Clin Microbiol Infect. 2012;18:797–807. PubMed https://doi.org/10.1111/j.1469-0691.2011.03701.x

8. Burbelo PD, Goldman R, Mattson TL. A simplified immunoprecipitation method for quantitatively measuring antibody responses in clinical sera samples by using mammalian-produced Renilla luciferase-antigen fusion proteins. BMC Biotechnol. 2005;5:22. PubMed https://doi.org/10.1186/1472-6750-5-22
9. Burbelo PD, Ching KH, Klimavicz CM, Iadarola MJ. Antibody profiling by luciferase immunoprecipitation systems (LIPS). J Vis Exp. 2009;32:1549. https://doi.org/10.3791/1549

10. Ko JH, Muller MA, Seok H, Park GE, Lee JY, Cho SY, et al. Suggested new breakpoints of anti-MERS-CoV antibody ELISA titers: performance analysis of serologic tests. Eur J Clin Microbiol Infect Dis. 2017;36:2179–86.

11. Drosten C, Meyer B, Müller MA, Corman VM, Al-Masri M, Hossain R, et al. Transmission of MERS-coronavirus in household contacts. N Engl J Med. 2014;371:828–35. PubMed https://doi.org/10.1056/NEJMoa1405858

12. Müller MA, Meyer B, Corman VM, Al-Masri M, Turkestani A, Ritz D, et al. Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study. Lancet Infect Dis. 2015;15:559–64. PubMed https://doi.org/10.1016/S1473-3099(15)70090-3
### Appendix Table. Serologic responses of Middle East respiratory syndrome coronavirus, South Korea, 2015

| Disease severity | Pt | 6 mpi | 9 mpi | 12 mpi | 6 mpi | 9 mpi | 12 mpi | 6 mpi | 9 mpi | 12 mpi | 6 mpi | 9 mpi | 12 mpi | 6 mpi | 9 mpi | 12 mpi | 6 mpi | 9 mpi | 12 mpi |
|------------------|----|-------|-------|--------|-------|-------|--------|-------|-------|--------|-------|-------|--------|-------|-------|--------|-------|-------|--------|
| Severe           |    |       |       |        |       |       |        |       |       |        |       |       |        |       |       |        |       |       |        |
| C                | 3.30 | 2.35  | 4.03  | 3.24 (6400) | 3.11 (3200) | 3.44 (12800) | 1685 | 490 | 707 | 640  | ND   | ND   | 55.4  | 59.3  | 84.2  |
| D                | 2.91 | 2.04  | 2.28  | 3.27 (12800) | 3.18 (6400) | 3.12 (3200) | 1734 | 689  | 581  | ND   | ND   | 80   | 92.2  | 106.2 | 121.3 |
| F                | 1.29 | 1.21  | 1.09  | 2.99 (1600) | 2.77 (1600) | 2.65 (1600) | 370  | 358  | 293  | ND   | ND   | 160  | 43.3  | 51.5  | 47.7  |
| G                | 2.59 | 2.35  | 1.90  | 3.21 (3200) | 3.19 (3200) | 3.01 (3200) | 740  | 693  | 551  | ND   | ND   | 80   | 84.3  | 92.3  | 111.0 |
| H                | 2.15 | 1.38  | 1.39  | 3.09 (3200) | 2.82 (1600) | 2.76 (1600) | 468  | 332  | 347  | ND   | ND   | 40   | 182.1 | 69.3  | 100.6 |
| Mild             |    |       |       |        |       |       |        |       |       |        |       |       |        |       |       |        |       |       |        |
| L                | 1.72 | NA    | 1.14  | 3.06 (3200) | NA    | 2.64 (1600) | 407  | NA   | 203  | ND   | ND   | 40   | 74.2  | NA    | 58.0  |
| M                | 0.47 | 0.43  | 0.47  | 2.1 (1600) | 1.7 (800) | 1.87 (800) | 80   | 93   | 76   | ND   | ND   | <20  | 39.4  | 33.5  | 27.8  |
| N                | 0.10 | 0.12  | 0.12  | 0.4 (<100)  | 0.41 (<100) | 0.45 (<100) | <20  | <20  | <20  | ND   | ND   | <20  | 8.3   | 3.5   | 9.0   |
| O                | 1.80 | 1.44  | 1.37  | 2.67 (6400) | 2.84 (3200) | 2.74 (3200) | 371  | 274  | 292  | ND   | ND   | 80   | 61.9  | 142.4 | 147.0 |
| P                | 0.60 | 0.34  | 0.38  | 0.78 (800) | 0.77 (400) | 0.73 (400) | 133  | 98   | 87   | ND   | ND   | 20   | 55.2  | 53.3  | 54.5  |

*Red type indicates serum samples that tested negative in each assay. LU, luminescence units; mpi, months post-infection; N-LIPS, nucleocapsid luciferase immunoprecipitation assay; OD, optical density; PRNT<sub>90</sub>, >90% plaque-reduction neutralization test; Pt., patient; S1, spike S1 protein.
Appendix Figure 1. Kinetics of MERS-CoV specific S1, S2, N and neutralizing antibody responses in 2 patients with Middle East respiratory syndrome. We tested antibody responses in serum samples using (A) an inhouse S1 ELISA (iELISA); (B) a routinely used S1 ELISA (rELISA); (C) S1 microarray; (D) plaque reduction neutralization test (PRNT); (E) nucleocapsid luciferase immunoprecipitation assay (N-LIPS); (F) S2 ELISA. Shown are antibody responses in time for serum from 2 patients (red, patient 1; black, patient 2). The dotted lines show the cutoff for each assay. LU, luminescence units, N-LIPS, nucleocapsid luciferase immunoprecipitation assay; OD, optical density at 450 nm; PRNT₉₀, 90% reduction in plaque reduction neutralization test; and RFU, relative fluorescence units.
Appendix Figure 2. Effect of lowering the assay cutoff on the specificity and sensitivity of the rELISA for detection of MERS-CoV specific antibodies. The overall specificity and sensitivity of rELISA in the specificity cohorts A–C and sensitivity cohorts D–H. Graph shows the ratio of optical density of sample to kit calibrator for study cohorts. Dotted lines indicate different cutoffs (OD ratio 1.1, 0.4, 0.3, 0.2). The table shows the number and percentage specificity (cohorts A–C; n = 195) and sensitivity in PCR-confirmed cases (cohorts F, G, H; n = 13). Cohorts: A, healthy blood donors (n = 50); B, acute non-CoV respiratory infections (n = 85); C, acute to convalescent non-MERS-CoV respiratory infections (n = 60); D, S1-microarray positive persons with camel contact (n = 18; blue; D1) and S1-microarray negative persons with camel contacts (n = 19; gray; D2); F–H, PCR-confirmed MERS-CoV–infected patients (n = 13).